Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Y-Mabs Therapeutics ( (YMAB) ) is now available.
Y-mAbs Therapeutics, Inc. has released a corporate overview presentation on its investor relations website, which includes updates on its business operations, clinical trials, and development pipeline. This presentation is intended for investor meetings and a podium presentation at the J.P. Morgan Healthcare Conference, indicating the company’s ongoing engagement with investors and stakeholders in the biopharmaceutical industry.
More about Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of novel antibody-based products for the treatment of cancer. The company is involved in clinical trials and has a development pipeline catering to oncology treatments.
YTD Price Performance: -13.55%
Average Trading Volume: 292,621
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $308.6M
See more insights into YMAB stock on TipRanks’ Stock Analysis page.
